Cymabay Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

CymaBay Therapeutics

11/11/2021 06:49

* Cymabay Therapeutics Inc  CBAY.OQ  reported a quarterly
adjusted loss of 33 cents​​ per share for the quarter ended in
September. The mean expectation of nine analysts for the quarter
was for a loss of 26 cents per share.
* Reported revenue was zero​;  analysts expected $6.25 million. 
* Cymabay Therapeutics Inc's reported EPS for the quarter was a
loss of 33 cents​.
* The mean earnings estimate of analysts had risen by about 1.7%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Cymabay Therapeutics Inc shares had risen by 17.3% this
quarter and lost 25.4% so far this year.
* The company reported a quarterly loss of $22.68 million.
* Wall Street's median 12-month price target for Cymabay
Therapeutics Inc is $12.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 11 at 06:49 a.m.
 ​All figures in US dollars unless otherwise stated